

# Leonard H Wexler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7527747/publications.pdf>

Version: 2024-02-01

43  
papers

6,698  
citations

236833

25  
h-index

276775

41  
g-index

43  
all docs

43  
docs citations

43  
times ranked

12098  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by <i>RAS</i> and <i>RAF</i> mutations. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 131-137.	1.5	8
2	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. <i>Nature Communications</i> , 2022, 13, .	5.8	63
3	Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study. <i>Modern Pathology</i> , 2022, 35, 1644-1655.	2.9	12
4	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	5.7	74
5	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. <i>Molecular Cancer Research</i> , 2021, 19, 1146-1155.	1.5	14
6	Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. <i>JAMA Dermatology</i> , 2020, 156, 963.	2.0	20
7	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	13.5	691
8	Undifferentiated round cell sarcoma with <i>BCOR</i> internal tandem duplications (ITD) or <i>YWHAE</i> fusions: a clinicopathologic and molecular study. <i>Modern Pathology</i> , 2020, 33, 1669-1677.	2.9	29
9	<i>NTRK3</i> overexpression in undifferentiated sarcomas with <i>YWHAE</i> and <i>BCOR</i> genetic alterations. <i>Modern Pathology</i> , 2020, 33, 1341-1349.	2.9	53
10	Pediatric rhabdomyosarcoma with bone marrow metastasis. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28219.	0.8	22
11	Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1151-1157.	0.4	14
12	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27869.	0.8	57
13	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	15.2	282
14	Novel intraoperative radiotherapy utilizing prefabricated custom three-dimensionally printed high-dose-rate applicators. <i>Brachytherapy</i> , 2019, 18, 277-284.	0.2	6
15	Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 108.	1.3	49
16	<i>MYOD1</i> -mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. <i>Modern Pathology</i> , 2019, 32, 27-36.	2.9	126
17	<i>BCOR-CCNB3</i> Fusion Positive Sarcomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 604-615.	2.1	207
18	Central nervous system relapse of rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26710.	0.8	27

#	ARTICLE	IF	CITATIONS
19	When treatment does not work: failure to understand failure. <i>Lancet Oncology</i> , The, 2018, 19, 1004-1006.	5.1	0
20	Morbidity and mortality after treatment of Ewing sarcoma: A singleâ€“institution experience. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26562.	0.8	27
21	Paratesticular rhabdomyosarcoma: Importance of initial therapy. <i>Journal of Pediatric Surgery</i> , 2017, 52, 304-308.	0.8	17
22	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26409.	0.8	66
23	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. <i>JCO Precision Oncology</i> , 2017, 2017, 1-11.	1.5	36
24	Jaw in a Day. <i>Journal of Craniofacial Surgery</i> , 2016, 27, 2101-2104.	0.3	48
25	A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1 -mutant sclerosing are associated with unfavorable outcome. <i>Oral Oncology</i> , 2016, 61, 89-97.	0.8	32
26	Long-term effect of chemotherapyâ€“intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 383-392.	0.3	25
27	Late Toxicities of Intensityâ€“Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1608-1614.	0.8	46
28	A singleâ€“center experience with undifferentiated embryonal sarcoma of the liver. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2246-2248.	0.8	13
29	Clinical and molecular heterogeneity of head and neck spindle cell and sclerosing rhabdomyosarcoma. <i>Oral Oncology</i> , 2016, 58, e6-e11.	0.8	23
30	Metastatic Rhabdomyosarcoma: Still Room for Improvement. <i>Journal of Clinical Oncology</i> , 2016, 34, 105-106.	0.8	11
31	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	3.2	251
32	Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Preâ€“metastatic Niche. <i>Cancer Research</i> , 2016, 76, 1335-1347.	0.4	112
33	Second cancer risk in childhood cancer survivors treated with intensityâ€“modulated radiation therapy (IMRT). <i>Pediatric Blood and Cancer</i> , 2015, 62, 311-316.	0.8	16
34	Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor. <i>Sarcoma</i> , 2015, 2015, 1-9.	0.7	21
35	Tumour exosome integrins determine organotropic metastasis. <i>Nature</i> , 2015, 527, 329-335.	13.7	3,688
36	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. <i>Nature Genetics</i> , 2014, 46, 595-600.	9.4	152

#	ARTICLE	IF	CITATIONS
37	Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1136-1142.	0.4	61
38	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a025650-a025650.	2.9	60
39	20-Year Experience With Intraoperative High-Dose-Rate Brachytherapy for Pediatric Sarcoma: Outcomes, Toxicity, and Practice Recommendations. International Journal of Radiation Oncology Biology Physics, 2014, 90, 362-368.	0.4	31
40	Patterns of Failure for Rhabdomyosarcoma of the Perineal and Perianal Region. International Journal of Radiation Oncology Biology Physics, 2014, 89, 82-87.	0.4	19
41	Positron Emission Tomography (PET) Evaluation After Initial Chemotherapy and Radiation Therapy Predicts Local Control in Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 996-1002.	0.4	49
42	Combined modality treatment of Ewing's sarcoma of the maxilla. Head and Neck, 2003, 25, 168-172.	0.9	28
43	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. , 1996, 78, 901-911.		112